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Ewing’s sarcoma is the second most common bone malignancy aﬀecting children and young adults. The prognosis is especially
poor in metastatic or relapsed disease. The cell of origin remains elusive, but the EWS-FLI1 fusion oncoprotein is present in the
majorityofcases.TheunderstandingofthemolecularbasisofEwing’ssarcomacontinuestoprogressslowly.EWS-FLI1aﬀectsgene
expression, but other factors must also be at work such as mutations, gene copy number alterations, and promoter methylation.
This paper explores in depth two molecular aspects of Ewing’s sarcoma: copy number alterations (CNAs) and methylation. While
CNAs consistently have been reported in Ewing’s sarcoma, their clinical signiﬁcance has been variable, most likely due to small
sample size and tumor heterogeneity. Methylation is thought to be important in oncogenesis and balanced karyotype cancers such
as Ewing’s, yet it has received only minimal attention in prior studies. Future CNA and methylation studies will help to understand
the molecular basis of this disease.
1.Introduction
Ewing’s sarcoma is a highly malignant tumor of chil-
dren and young adults. The molecular mechanisms that
underlie Ewing’s sarcoma development are beginning to be
understood, but the genetic risk factors leading to disease
susceptibility remain largely unknown. Ewing’s sarcoma
is the second most common pediatric bone cancer after
osteosarcoma, with 30–60% survival depending on tumor
site and metastases at diagnosis [1, 2]. When patients with
Ewing’s sarcoma relapse, it is usually fatal: less than 20% sur-
vive [3–5]. Beyond incremental improvements in cytotoxic
chemotherapyregimens,therehavebeennomajortreatment
advances in the last 20 years [6, 7]. Clinical features are
the only markers that have been found to correlate reliably
with the outcome in Ewing’s sarcoma, but no risk-adapted
therapy has proven successful; worse prognosis in Ewing’s
is predicted by metastatic disease measured by imaging
and bone marrow examination, larger tumor volume, and
primary tumors in the pelvis [8]. While osteosarcoma is
thought to originate from bone cell progenitors [9], the
cell of origin of Ewing’s sarcoma is less clear with some
evidence suggesting that tumors arise from a mesenchymal
stem or progenitor cells [10–12]. Other researchers in the
ﬁeld believe instead that Ewing’s sarcoma develops from
a neuroectodermal origin [13–17]. The lack of a known
cell of origin contributes to the diﬃculty in understanding
exactly how Ewing’s sarcoma develops or even how to design
laboratory experiments to study tumorigenesis.
Nearly every case of Ewing’s sarcoma contains a translo-
cation involving the EWSR1 gene on chromosome 22. The
most common rearrangement is t(11;22)(q24;q12), which
generates the EWS-FLI1 fusion oncogene, found in ∼85% of
Ewing’s cases [18–21]. The translocation t(21;22)(q22;q12)2 Sarcoma
is found in another 10% of cases [21, 22] and the remainder
of EWS translocations utilize a variety of fusion partners
from the ETS family of transcription factors [19, 20]. All
of the Ewing’s sarcoma fusion proteins contain a strong
transcriptional activation domain fused to a DNA-binding
domain and function as aberrant transcription factors
that dysregulate a number of target genes and contribute
to oncogenic transformation [18–21, 23–30]. The EWS-
FLI1 translocation is the best understood and most well-
characterized molecular aspect of Ewing’s sarcoma. This
translocation (or one of the alternates) is thought to be
necessary but not suﬃcient to cause disease [31].
In addition to translocations, neoplastic development
in cancer depends on other acquired molecular changes.
Such changes in tumor biology include copy number alter-
ations (CNAs), such as genomic deletions or ampliﬁcations,
and methylation abnormalities. As newer technology has
become available in recent years, we have learned more
about CNAs and methylation in Ewing’s sarcoma and
possible associations with outcome, disease classiﬁcation,
andtumorigenesis.Thesemolecularinvestigationshavebeen
limited by the rarity of Ewing’s sarcoma and the small tumor
samples obtained at initial diagnostic biopsy available for
analysis. Nevertheless, many overlapping regions of CNAs
and methylation have been described; their underlying
signiﬁcance is not always clear. Further exploration as to
how these changes aﬀect the outcome and their prevalence is
essential to the development of future treatment options. In
this paper, we describe the reported CNAs and methylation
changes associated with Ewing’s sarcoma and any known
clinical correlations with these molecular ﬁndings.
2.MaterialsandMethods
Literature searches for articles containing “Ewing’s sarcoma
copy number” and “Ewing’s sarcoma methylation” were
performed via the PUBMED database. Results consisted of
15 separate journal articles for copy number and 14 for
methylation. Twelve relevant publications were selected for
copy number and their references explored and included
when appropriate. Nine relevant promoter methylation
articles were selected and their references explored.
3. Results andDiscussion
3.1. Ewing’s Sarcoma and Copy Number Alterations (CNAs).
Speciﬁc CNAs predict prognosis in several cancers and
have been introduced as part of clinical risk stratiﬁcation
for colorectal and breast cancer, neuroblastoma, and brain
tumors [32–35]. Despite intense investigation of Ewing’s
sarcoma biology, very few molecular markers have been
discovered for routine clinical use in this disease. In contrast,
active risk stratiﬁcation based on molecular cytogenetics has
increased the cure rate for childhood acute lymphoblastic
leukemia (ALL) from less than 50% to over 85% in only
a few decades [36]. Moreover, the use of high-resolution
single nucleotide polymporphism (SNP) technology has
been used to identify recurring CNAs in childhood leukemia
[37–42] including relapsed cohorts [43, 44]. The study of
CNAs in cancer also helps to better classify and under-
stand the development of disease. For example, CDKN2A
homozygous deletions in pediatric gliomas were recently
found to signiﬁcantly associate with speciﬁc BRAFV600E
mutations, helping to deﬁne a new subset of tumors [45];
the same deletion and mutation were also shown to work
togethertopromotegliomaformationinmice,validatingthe
cooperation between CNAs and mutations [46].
New genomic technology has proven eﬀective in deter-
mining copy number changes in a variety of tissue types.
Previously, DNA extracted from paraﬃnh a sb e e nt o o
degraded to yield reliable data for analysis, but a new
molecular inversion probe assay (OncoScan, Aﬀymetrix,
Santa Clara, CA) has been used successfully to identify
copy number changes in formalin-ﬁxed paraﬃn-embedded
(FFPE) samples [65]. The ability to now interrogate FFPE
samples allows the analysis of archival tissues and increases
sample sizes for future Ewing’s sarcoma studies. Copy
number assessment in combination with clinical data could
be used to identify CNAs in archival tissue and determine
their link to the outcome in Ewing’s sarcoma. Moving
forward,candidatelocicouldbefurtherstudiedinvitroorin
pre-clinical animal models to determine their contribution
to drug resistance and tumor progression.
A large number of novel and recurrent secondary
abnormalities in Ewing’s tumors relating to copy number
already have been discovered (see summary Table 1). The
vast majority of copy number studies thus far in Ewing’s
sarcoma have been performed with comparative genomic
hybridization (CGH) technology on either cell lines or
primary samples. The most commonly reported CNAs in
Ewing’s sarcoma are trisomies of chromosomes 8 and 12
followed by the gain of 1q [47–49, 51–57, 66, 67]. Trisomy 8
is of particular interest as it occurs consistently and often in
high frequency, being reported in >50% of cases in Ewing’s
sarcoma [47, 56, 57]. The oncogene, MYC, is thought to be
a possible candidate driver of trisomy 8 as it was shown to
bestow a selective advantage through nonfocal ampliﬁcation
when studied in undiﬀerentiated soft tissue sarcomas [67].
In contrast to these ﬁndings, many studies have not found
a statically signiﬁcant link to survival outcomes in Ewing’s
sarcoma and trisomy 8 [47, 51, 54, 56]. Despite the lack
of statistical signiﬁcance, some evidence does suggest a link
between trisomy 8 and worse outcome or worse overall
survival. Values for 5-year distant disease-free survival (P =
.16) and overall survival (P = .39) were not statistically
signiﬁcant, but the percentage of trisomy 8 was greater in
both survival categories implicating a possible, though not
statistically relevant, trend [54]. Focal ampliﬁcations in both
the long and short arms of chromosome 8 (opposed to the
entire trisomy) have been associated with clinical outcomes
in Ewing’s sarcoma. Speciﬁcally, Ozaki et al. reported that 8p
ampliﬁcations occurred at higher frequency in relapsed cases
comparedtoprimarytumors(P = .04)[48].Theyalsofound
that combinations of CNAs, including 8q ampliﬁcation
in conjunction with chromosome 20 ampliﬁcations, were
signiﬁcant for worse cumulative overall survival rates (P =
.0065) [48]. Savola et al. have proposed WDR67 (8q24.13)
and GSDMD1 (8q24.3) as interesting candidate genes forSarcoma 3
Table 1: Summary of copy number alternations (CNAs) in Ewing’s Sarcoma (tumor, cell line, and xenograft) in published literature.
Deletion Gain Ewing’s
sample type Frequency (%) Technology Study Clinical signiﬁcance
1p ESFT 17/184 (9%) Karyotyping
and CGH
Hattinger et al. [47];
Ozaki et al. [48]
1p36 ESFT 5/88 (6%) Karyotyping
(G-Band) Roberts et al. [49]
1p36.32-p36.11 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
1q ESFT 77/396 (19%) Karyotyping
and CGH
Armengol et al. [51];
Brisset et al. [52];
Hattinger et al. [47];
Ozaki et al. [48];
Roberts et al. [49];
Savola et al. [53];
Tarkkanen et al. [54]
(i)Adverse event free survival
(ii) Adverse overall survival
(iii) Age at diagnosis >15 years
(iv) Metastatic (trend)
Cell line 5/8 (63%) CGH Shing et al. [55]
1q21-q22 ESFT 5/28 (18%) CGH Tarkkanen et al. [54]
(i)Adverse overall survival (trend)
(ii) Adverse 5-year distant
disease-free survival (trend)
2 ESFT 38/262 (15%) Karyotyping
and CGH
Brisset et al. [52];
Hattinger et al. [47];
Roberts et al. [49],
Savola et al. [53]
(i)Localized disease
2q ESFT 12/62 (19%) CGH Ozaki et al. [48] (i)Adverse overall survival
3p Cell line 3/8 (38%) CGH Shing et al. [55]
4p ESFT 10/105 (10%) CGH Brisset et al. [52];
Ozaki et al. [48] (i) Relapse
5 ESFT 28/231 (12%) Karyotyping
and CGH
Brisset et al. [52];
Hattinger et al. [47];
Roberts et al. [49]
5p ESFT 5/25 (20%) CGH Ferreira et al. [56]
6p21.1∼pter ESFT 3/28 (11%) CGH Tarkkanen et al. [54]
(i)Adverse overall survival
(ii) Adverse 5-year distant
disease-free survival
7 ESFT 26/216 (12%) Karyotyping
and CGH
Hattinger et al. [47];
Roberts et al. [49];
Tarkkanen et al. [54]
7p21.1-p11.2 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
7q (partial) ESFT 6/25 (25%) CGH Ferreira et al. [56]
7q ESFT 5/28 (18%) CGH Tarkkanen et al. [54]
8 ESFT 197/413 (48%) Karyotyping,
CGH and FISH
Armengol et al. [51];
Brisset et al. [52];
Ferreira et al. [56];
Hattinger et al. [47];
Maurici et al. [57];
Ozaki et al. [48];
Savola et al. [53];
Tarkkanen et al. [54];
Zielenska et al. [58]
(i)Local recurrences (trend)
(ii) Relapse (trend)
(iii) Adverse overall survival (trend)
(iv) Adverse 5-year distant
disease-free survival (trend)
Cell line 8/8 (100%) CGH Shing et al. [55]
8p ESFT 30/62 (48%) CGH Ozaki et al. [48] (i)Relapse
8q ESFT 32/62 (52%) CGH Ozaki et al. [48]
8q11.21-q22.3 ESFT 6/9 (67%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
8q24.11-q24.21 ESFT 7/9 (78%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]4 Sarcoma
Table 1: Continued.
Deletion Gain Ewing’s sample
type Frequency (%) Technology Study Clinical signiﬁcance
9p ESFT 7/31 (23%) CGH Savola et al. [53]







Brownhill et al. [59];
Huang et al. [60];
Kovar et al. [61];
Neale et al. [50];
Roberts et al. [49];
Savola et al. [62];
Wei et al. [63]
(i)Adverse event free survival (trend)
(ii) Adverse overall survival
(iii) Axial
(iv) progressive disease (trend)
(v) Poor chemoresponse







Brownhill et al. [59];
Kovar et al. [61];
Savola et al. [62]
9p21.3 Xenotransplant 4/12 (33%) dPCR, FISH L´ opez-Guerrero et al.
[64]
10 ESFT 12/87 (14%) CGH Ferreira et al. [56];
Ozaki et al. [48]
11p ESFT 2/62 (3%) Ozaki et al. [48] (i)Relapse
11q ESFT 2/62 (3%) Ozaki et al. [48] (i) Relapse
12 ESFT 104/434 (24%) Karyotyping,
CGH and FISH
Armengol et al. [51];
B r i s s e te ta l[ 52];
Ferreira et al. [56];
Hattinger et al. [47];
Maurici et al. [57];
Roberts et al. [49];
Savola et al. [53];
Tarkkanen et al. [54];
Zielenska et al. [58]
(i) Adverse event free survival
(ii) Adverse overall survival
(iii) Relapse (trend)







Ozaki et al. [48]
Shing et al. [55] (i) Adverse overall survival
12q14.1-q15 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
14 ESFT 11/143 (8%) Karyotyping
and CGH
B r i s s e te ta l .[ 52];
Hattinger et al. [47]
14q11.2 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
15 ESFT 4/43 (9%) CGH Brisset et al. [52]
16p ESFT 2/28 (7%) CGH Tarkkanen et al. [54]
16q ESFT 69/396 (17%) Karyotyping
and CGH
B r i s s e te ta l .[ 52];
Ferreira et al. [56];
Hattinger et al. [47];
Ozaki et al. [48];
Roberts et al. [49];
Savola et al. [53];
Tarkkanen et al. [54]
(i) Adverse overall survival
(ii) Age at diagnosis >15 years
(iii) Disseminated disease at diagnosis
16q Cell line 5/8 (63%) CGH Shing et al. [55]
16q22.3 ESFT 5/9 (56%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]Sarcoma 5
Table 1: Continued.
Deletion Gain Ewing’s sample
type Frequency (%) Technology Study Clinical signiﬁcance
17 ESFT and








Ozaki et al. [48]
Shing et al. [55] (i) Adverse overall survival
17p13 ESFT 8/88 (9%) Karyotyping
(G-Band) Roberts et al. [49]
17q21.31-q25.3 ESFT 6/9 (67%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
18 ESFT 6/68 (9%) CGH B r i s s e te ta l .[ 52];
Ferreira et al. [56]
19 ESFT 4/25 (16%) CGH Ferreira et al. [56]
19p ESFT 7/62 (11%) CGH Ozaki et al. [48]
19q ESFT 11/62 (18%) CGH Ozaki et al. [48]
20 ESFT 35/248 (14%) Karyotyping and
CGH
B r i s s e te ta l .[ 52];
Ferreira et al. [56];
Hattinger et al. [47];
Roberts et al. [49]
(i) Adverse event free survival
(ii) Adverse overall survival
20p ESFT 11/62 (18%) CGH Ozaki et al. [48] (i) Adverse overall survival
20q ESFT 11/62 (18%) CGH Ozaki et al. [48] (i) Adverse overall survival
20q11.23-
q13.33 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
21q22.3 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
22q11.21 ESFT 2/9 (22%) SNP Microarray
(Aﬀy 100K) Neale et al. [50]
Y Cell lines 3/5 (60%) CGH Shing et al. [55]
∗Modiﬁed from Toomey et al. Oncogene 2010. ESFT:Ewing’s Sarcoma Family of Tumors, CGH:comparative genomic hybridization.
tumorigenesis and progression as part of 8q ampliﬁcation
that warrant future investigation based on their integrated
outcome analysis (P<. 001 and P<. 001, resp.) [53].
Trisomy 12 has been suggested to be linked to trisomy
8. While one study found that every case with trisomy 12
was combined with trisomy 8 [51], others state the these
trisomies are independent events [57]. The frequency of
trisomy 12 occurring with trisomy 8 is higher than trisomy
12alone,butbotheventshavebeenshowntooccurindepen-
dently [47, 57]. Copy number gains of 8 and/or 12 appear
more frequently in local recurrences (83% of the time)
compared to primary (47%) and metastatic (42%) lesions
and are hypothesized to appear with increased frequency
during tumor progression or after initial translocation [57].
Much like trisomy 8, trisomy 12 has conﬂicting information
regarding its clinical signiﬁcance. However, many studies
seem to suggest that trisomy 12 or focal ampliﬁcations
on chromosome 12, are more important than those for
chromosome 8. Trisomy 12 correlates to adverse-event-free
survival (P = .009) for individuals with localized disease
[47]. Even though other reports of this trisomy show no
statistical signiﬁcance for overall survival (P = .67) [54],
evidence to the contrary links aberrations on 12p and 12q
to reduced overall survival by univariate analysis (P = .039
andP = .019)[48].InonesetofEwing’stumors,thesmallest
region of shared ampliﬁcation on chromosome 12 contained
two known oncogenes, ERBB3 and CDK4 [53]. These genes
maybeindicativeoftheimportanceoftrisomy12anditsrole
in tumorigenesis.
Ampliﬁcations and trisomies involving chromosomes
8 and 12 have conﬂicting ﬁndings regarding clinical and
statistical signiﬁcance. This is due to either the lack of
statistical power in small sample sizes or the variable nature
ofthedisease.Ineithercase,neithertrisomywasshowntobe
associated with improved prognostic outcome. This contrasts
with descriptions of chromosome 2, which Brisset et al.
reported to correlate with localized tumors rather than
metastatic disease (P = .02) [52]. However, again illustrating
the variable nature of copy number studies in Ewing’s
sarcoma, Ozaki et al. described the association between gains
of 2q and the reduction of overall survival (P = .022)
[48]. Perhaps the gain in chromosome 2 (speciﬁcally 2q)
correlates with the more unusual localized tumors that also
lead to relapse. Larger studies will be needed to clarify the
importance of this ampliﬁcation.
The gain of 1q is often reported with the loss of 16q.
This is the presumed artifact of an unbalanced translocation
in Ewing’s sarcoma, der(16)t(1;16) [47, 48, 51, 52, 54, 55,
66, 68]. Though it is diﬃcult to separate the translocation’s
downstream eﬀects from the resulting CNA’s impact, speciﬁc6 Sarcoma
clinical factors were linked to 16q loss such as age at
diagnosis >15 years and disseminated disease at diagnosis
(P = .035 and P = .038, resp.) [47]. The gain of 1q and
the loss of 16q in combination with chromosome 12 gain
also demonstrated an increased frequency of them occurring
together (P<. 0001) [47]. The region of 1q gain, regardless
of localized or disseminated disease, was determined to be
signiﬁcant for both adverse overall survival (localized disease
P = .002; disseminated disease P = .029) and event-free
survival (localized disease P = .018; disseminated disease
P = .010) [47]. While 1q ampliﬁcation showed no statistical
signiﬁcance in other studies, a high-level focal ampliﬁcation
was found at 1q21-q22 [51], two genes also reported in
other sarcoma samples [69], SPRR3 with 5 copies and FLG
with 4 copies were aﬀected [51]. Other suspected candidates
in 1q21-22 locus include CACY and CAPL,b o t ho fw h i c h
have been implicated in tumor progression and metastasis
[51, 70]. 1q21-1q22 ampliﬁcation has also been reported
in other sarcomas [69, 71]. This more focal 1q gain lacked
statistical signiﬁcance but still suggested association with
adversedistantdisease-freesurvivalandoverallsurvival[54].
Similar to the pairing of CNAs of 1q gain and 16q loss,
combined losses of 16q and 17p, resulting from another
unbalanced translocation, have been described [48, 55].The
loss of concomitant 16q and 17p has demonstrated lower
overall survival (P = .0012) [48]. 17p loss may have its major
impact by encompassing the loss of the well-known tumor
suppressor, TP53 [47, 64, 72]. In addition to TP53 deletion
that is contained within 17p loss, mutation of TP53 has been
reported to show an association with poor chemoresponse
and overall survival in Ewing’s sarcoma (P = .03 and P<
.001) [60].
Deletion of 9p21 encompassing CDKN2A (p16-INK4a)
appeared in 10–73% of cases, including Ewing’s sarcoma cell
lines [50, 53, 59–62], with reported homozygous deletions in
8% [56] and 13% [60] of patient samples. This CDKN2A
deletion was found to be a negative predictor of disease-
speciﬁc survival (P = .001): 7 patients with this deletion all
died of disease before 36 months, 2 of which had metastases
atdiagnosis[63].Thecombinationof CDKN2Adeletionand
TP53mutationwasshowntobethemostsigniﬁcantnegative
predictor of overall survival (P<. 001) [60]. Our own
experience has demonstrated the 9p21 deletion to be much
more common in cell lines (80%) than clinical samples (5%)
(unpublished). Current studies validating the prevalence
and prognostic signiﬁcance of CDKN2A deletions and TP53
mutations in Ewing’s sarcoma are underway through the
Children’s Oncology Group (COG).
3.2. Genomic Instability. Instability of cancer genomes leads
to the accumulation of CNAs. Early ﬁndings showed no
statistical link between total number of CNAs and worse
outcome in Ewing’s sarcoma [51]. However, later data
indicated that unstable karyotypes with higher numbers of
CNAs in Ewing’s tumors may be a correlate with worse
outcome [53, 55, 56, 58]. CNAs totaling above three had
worse prognosis in relation to event-free and overall survival
(P = .049 and P = .030) [53]. By clustering patients
into two groups of genomic instability and stable genomes,
prognostic signiﬁcance was determined for overall survival
via univariate and multivariate analysis (P = .017 and P =
.034) [56]. The group with increased genomic instability
contained areducedpercentageof patients toreachcomplete
remission, speciﬁcally 64% versus 100% [56].
3.3. Copy Number Mitochondrial Data. Mitochondrial DNA
(mtDNA) copy number changes have been associated with
increased risk of certain cancers. To date, breast cancer and
renal cell carcinoma both have been associated with an
increase in mtDNA and a decrease in mtDNA, respectively
[73–75].Thedisplacement-(D-)loopofmitochondrialDNA
(mtDNA),anoncodingregioncomprisedof1,124basepairs,
is more prone to mutation. These mutations, in conjunction
with quantitative mtDNA changes, have been linked to
Ewing’s sarcoma [75, 76]. The D-loop’s increased mutation
stems from its vulnerability to oxidative damage and reduced
reparation capacity [75]. Decreased copy number of mtDNA
is more often found in samples containing D-loop mutations
(P = .04) and could be a result of the transcriptional
and replicating functions of the D-loop [75]. While both
D-loop mutations and reduced content of mtDNA are at
higher instance in Ewing’s sarcoma, the greatest statistical
signiﬁcance was determined to be between low mtDNA copy
number and tumor metastasis as all of the metastases in the
study contained low numbers of mtDNA (P = .029) [75].
3.4.Ewing’sSarcomaandMethylationData. Ofthevastarray
of oncogenic manipulations of gene expression achieved in
malignantcells,notallarisefromeitherrandommutationor
cytogenetic gains and losses resulting in CNAs. Methylation
is an alternate method by which gene expression is changed
in cancer cells [77]. Methylation is the addition of a methyl
group, usually to the 5
  position of the cytosine pyrimidine
ring, most importantly on cytosine residues contiguous to
guanine residues, in what are called CpG islands. CpG
sequences, in general, are relatively scarce in the human
genome, as spontaneous mutation of the C to a T residue is
especially common in the methylated state. Most remaining
CpGs in the human genome are in the 5
  regulatory and
promoter sequences of genes.
Methylation of these promoter CpGs provides a cell-
heritable means by which expression can be regulated. When
a new zygote is formed, the cell is extensively demethylated.
As cell division proceeds and eventually diﬀerentiation,
methylation also proceeds, silencing certain genes no longer
necessary along the cell’s prescribed diﬀerentiation course.
Methylation of promoter CpG islands aﬀects transcription
of the nearby gene via physical interruption of the binding
of transcription factors and by encouraging binding of
methyl-CpG-binding domain proteins. This recruits his-
tone deacetylase and other chromatin-remodeling proteins,
resultingintightchromatinpackagingofthelocusandexclu-
sion of transcriptional machinery. This silenced state of the
gene is then passed on to daughter cells. Normal methylation
is an important developmental program by which dangerous
genes, such as viral sequences integrated into the human
genome over generations, and early developmental genes can
be silenced when necessary.Sarcoma 7
Cancer cells can have a variety of problems with methy-
lation. Some powerful oncogenes from integrated viruses
and developmental genes that engender a highly proliferative
state are often demethylated in cancers, resulting in their
aberrant and deleterious expression. In addition, the pro-
moters of many tumor suppressor genes are over-methylated
resulting in their silencing. Obviously, genomic sequencing
or usual hybridization techniques will not detect promoter
methylation or demethylation. These powerful epigenetic
modiﬁcations of genes are only noted when speciﬁcally
sought. While dedicated eﬀorts are underway to understand
methylation in many cancer types, such large scale eﬀorts
are lacking for the Ewing’s sarcoma family of tumors. In
fact, the relative absence of wild karyotype anomalies and
rampant mutations argues that epigenetic modiﬁcations
such as methylation may be a prominent mechanism of
disease in sarcomas bearing balanced translocations such as
Ewing’s sarcoma. While methylation and epigenetics have
only received limited attention in the literature thus far, they
seem likely to be important genetic mechanisms for Ewing’s
sarcomagenesis and progression.
Two studies have assessed genetic alterations in the 9p21
locus in Ewing’s sarcoma [64, 78]. One identiﬁed 4 tumors
with homozygous deletion and 2 with promoter hyper-
methylation of CDKN2A among 26 tumors in total [64].
Two tumors had codeletion of CDKN2B (p15-INK4b) and 3
promoter hypermethylation of p15 [64]. The second study
found 1 methylated, 1 point-mutated, and 2 homozygous
deleted CDKN2A among 24 tumors, as well as 2 methylated
and 2 homozygous deleted CDKN2B [78].
Another gene studied with respect to promoter methyla-
tion in Ewing’s sarcoma is RASSF1A. One study interrogated
RASSF1A along with p16, MGMT, GSTP1, APC, DAPK,
RARβ, CDH1, and CDH13 and found only MGMT and
CDH1 promoters methylated in 1 of 8 (12.5%) Ewing’s
sarcoma tumor samples [79]. Failure to detect CDKN2A
promoter methylation in this study can be reconciled with
the results of the larger studies described above based simply
on insuﬃcient sample size. With respect to RASSF1A, these
r e s u l t sa r em o r ed i ﬃcult to reconcile with the high frequency
of RASSF1A methylation in a previously published report
[80]; Avigad et al. identiﬁed 21 of 31 (68%) patient samples
and 1 of 4 (25%) cell lines with hemizygous promoter
methylation and 2 of 4 (50%) cell lines with homozygous
promoter methylation. This larger study also correlated
reduced RASSF1A expression with promoter methylation in
12 tumors checked. Further, they demonstrated reexpression
of RASSF1A in the 2 homozygous methylated cell lines, upon
in vitro application of 5-aza-2  deoxycytidine, a powerful
demethylating agent.
Twostudieshavecorroboratedeachotherinidentifying1
of 4 (25%) and 9 of 41 (22%) Ewing’s cell lines with reduced
caspase 8 expression, secondary to promoter methylation
[81, 82]. The larger of these studies went further to conﬁrm
this reduced or lost caspase 8 expression by promoter
methylation as the mechanism by which the 9 cell lines
evaded TRAIL-induced apoptosis [82]. They conﬁrmed the
absence of deletions in the caspase 8 gene, as well as
the reexpression of caspase 8 upon 5-aza-2  deoxycytidine
administration. Reexpression restored TRAIL and cytotoxic
chemotherapy-induced apoptosis in these cell lines. They
further checked 20 primary Ewing’s sarcoma tumor samples,
where they identiﬁed the predominance of the methylated
caspase 8 promoter in 13 cases.
Finally, 5-aza-2  deoxycytidine-driven demethylation has
been tested as a means of disrupting the transformed pheno-
type of Ewing’s sarcoma cell lines [83]. Using a clonogenic
assay, demethylation alone dropped clonogenicity by 20
percent. Synergistic with a panel of histone deacetylase
inhibitors, eﬀects of 80 to 90 percent disruption of clono-
genicity were detected, in addition to the reexpression of
tumor suppressors such as E-cadherin and TSLC1.
4. Conclusions
In this paper, we focused primarily on copy number and
methylation data. We also acknowledge the importance
of other molecular changes potentially at work in Ewing’s
sarcomagenesis such as pleiotropic eﬀects of the chromo-
somal translocation beyond creation of the speciﬁc fusion
oncogene, somatic mutations in yet uninterrogated tumor
suppressors, increased expression of oncogenes or oncogenic
microRNAs, and other epigenetic mechanisms of expression
regulation such as histone and chromatin packaging that
could not be covered within the scope of this review. CNAs
and methylation changes in Ewing’s sarcoma, along with
some of these yet unexplored genetic and epigenetic pertur-
bationsmaybeessentialtoEwing’stumorigenesisasevidence
suggests that the EWS-FLI1 translocation is necessary but
not suﬃcient for Ewing’s transformation in vitro [31]; CNAs
and methylation changes may form some of the necessary
second hits required for Ewing’s sarcoma to develop. The
complex cooperative relationships of these many molecular
mechanisms of expression alteration have not been fully
explored, and a full-system biology approach may prove to
beinformative intheﬁeldof Ewing’ssarcoma.Asexplored in
thisreview,isolatedcombinationsofchromosomalgainsand
deletions already have begun to be described. Unfortunately,
the results of the limited copy number studies are rarely in
agreement likely due to poor statistical power in each small
sample studied. In many instances, statistical signiﬁcance
cannot be determined, but trends still suggest that these
CNAs have prognostic impact or contribute to genomic
instability associated with worse outcome.
The investigation of copy number in Ewing’s sarcoma
will continue to advance given the rapid acceleration of
high-resolution genomic technology to interrogate clinical
samples, including archived FFPE specimens. Discovery of
speciﬁc genes (rather than larger chromosomal cytobands)
associatedwithtumordevelopmentandoutcomewillextend
rapidly as the coverage in new SNP microarray platforms
continues to become more dense and whole genome
sequencing becomes more aﬀordable. Novel and recurrent
CNAs have been reported to cover nearly the entire genome.
The main copy number recurrences in Ewing’s sarcoma
included trisomies 8 and 12, along with 1q ampliﬁcation.
These ﬁndings were consistent throughout the majority of
studies,despitetheinabilityofmanystudiestoﬁndstatistical8 Sarcoma
signiﬁcance related to treatment response, prognosis, out-
come, or tendency to relapse. Although several recurring
regions, such as, 16q deletions, have been repeatedly shown
in diﬀerent copy number studies to be associated with
worse outcomes, these ﬁndings still await validation and
incorporation into clinical trials.
For methylation as a mechanism of sarcomagenesis, two
prominent tumor suppressor loci, CDKN2A and RASSF1A,
as well as one important apoptosis activator, caspase 8,
have been implicated. Further, functional assays have shown
the reversibility of these expression repressions by the
application of demethylating agents. For these methylation-
associated genetic perturbations, therapeutic implications
are very direct because the clinical drugs aﬀecting methy-
lation status and downstream histone deacetylation are
already available for patient use. We expect that researchers
have only scratched the surface of the Ewing’s methylome.
With the knowledge of demethylated oncogenes and other
methylation-silenced tumor suppressors, the mechanisms
leading to further CNAs and increased genomic instability
with tumor proliferation may be elucidated. The continued
investigation of copy number and methylation in Ewing’s
sarcomawillleadtoabetterunderstandingoftumorigenesis,
more accurate risk stratiﬁcation and hopefully new targets
for developmental therapeutics. As genomic technology con-
tinues to improve, CNA and methylation changesdetected in
clinical samples can be rapidly incorporated into patient care
to improve the outcome in Ewing’s sarcoma.
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